← Back to Clinical Trials
Recruiting NCT06933667

NCT06933667 Kimel Family Centre for Brain Health and Wellness

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06933667
Status Recruiting
Phase
Sponsor Baycrest
Condition Prevention
Study Type INTERVENTIONAL
Enrollment 450 participants
Start Date 2024-03-26
Primary Completion 2027-08-31

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Physical ActivityBrain-healthy EatingCognitive Engagement

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 450 participants in total. It began in 2024-03-26 with a primary completion date of 2027-08-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Participants (n=450; aged 50+; without a diagnosis of dementia; sufficiently fluent in English to complete the assessments and engage in programming) receive a comprehensive dementia risk assessment, including nonmodifiable and modifiable risk factors, from which they receive a Personalized Dementia Risk Report and Program Strategy, indicating their health conditions increasing and their risk level in five modifiable risk domains: physical activity, brain- healthy eating, cognitive engagement, social connections, and mental wellbeing. Equipped with this information, participants enroll in programs within the Centre to address their risk factors. Changes to their dementia risk, cognition, and Personalized Program Strategy are communicated through re-assessments of risk factors every six months (risk and cognition) and every year (comprehensive assessment).

Eligibility Criteria

Inclusion Criteria: * Aged 50 years or older * Sufficiently fluent in English to complete the assessments and participate in programming. Exclusion Criteria: * Diagnosis of dementia.

Contact & Investigator

Central Contact

Nicole D. Anderson, PhD, CPsych

✉ nanderson@research.baycrest.org

📞 416-785-2500

Principal Investigator

Nicole D. Anderson, PhD, CPsych

PRINCIPAL INVESTIGATOR

Baycrest

Frequently Asked Questions

Who can join the NCT06933667 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, studying Prevention. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06933667 currently recruiting?

Yes, NCT06933667 is actively recruiting participants. Contact the research team at nanderson@research.baycrest.org for enrollment information.

Where is the NCT06933667 trial being conducted?

This trial is being conducted at Toronto, Canada.

Who is sponsoring the NCT06933667 clinical trial?

NCT06933667 is sponsored by Baycrest. The principal investigator is Nicole D. Anderson, PhD, CPsych at Baycrest. The trial plans to enroll 450 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology